BYSI BeyondSpring, Inc.
Price Chart
Executive Summary
BeyondSpring presented updated Phase 2 data at ASCO 2026 for its triple combination (pembrolizumab + Plinabulin + docetaxel) in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors. The data showed median PFS of 7.0 months, a 24-month OS rate of 58.0%, and a manageable safety profile, which the company positions as favorable versus historical docetaxel benchmarks. As a clinical-stage biotech with a $72M market cap, this is a positive data readout but remains early-stage, and the stock has historically shown high volatility on such news.
Actionable Insight
The data are encouraging for Plinabulin's potential in post-ICI NSCLC, but the study is a single-arm Phase 2 with 47 patients. Traders should watch for next steps: regulatory discussions, Phase 3 plans, or partnership announcements. Given BYSI's small market cap and historical volatility, a binary outcome on future catalysts could drive large moves.
Key Facts
- Median PFS of 7.0 months vs historical 3.7-3.9 months for docetaxel in similar post-ICI populations.
- 24-month OS rate of 58.0% with median OS not yet reached.
- Disease control rate (DCR) of 79.5% and confirmed ORR of 18.2%.
- 53.2% of patients experienced grade 3+ treatment-related adverse events, with hypertension (17.0%) and neutropenia (17.0%) most common.
- Data presented at ASCO 2026, a key medical conference, lending credibility to the results.
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue. Positive data may increase probability of future regulatory success and partnership value.
Risk Factors
- Single-arm Phase 2 design limits comparability; results may not replicate in larger randomized trials.
- 53.2% grade 3+ AE rate, including neutropenia and hypertension, could raise safety concerns.
- No revenue or near-term approval timeline; stock is highly sensitive to pipeline milestones.
- Historical calibration shows mixed T+20 outcomes for BYSI, with high volatility and negative alpha on average.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304984 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
1d ago
|
8-K
| — | awaiting T+5 | — | — |
|
Jun 2, 2026
3d ago
|
Press Release
| — | awaiting T+5 | — | — |
|
May 13, 2026
23d ago
|
8-K
| $1.45 $1.29 | ▼ −11.03% | ▼ −9.88% | $1.71 (+17.93%) |
|
May 13, 2026
23d ago
|
Press Release
| $1.45 $1.29 | ▼ −11.03% | ▼ −9.88% | $1.71 (+17.93%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $1.61 $1.73 | ▲ +7.14% | ▲ +5.51% | $1.71 (+6.21%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $1.68 $1.71 | ▲ +1.79% | ▲ +2.03% | $1.71 (+1.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access